Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H- indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68)

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1003-1009

  Kitamura, Ryuichi ^a   Asanoma, Hisae ^a   Nagayama, Sekio ^a   Otagiri, Masaki ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; ISOPROTEIN; OMEPRAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIFAMPICIN;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONIDES; HEPATOCYTES; HUMANS; HYDROXYLATION; INDOLES; MICROSOMES, LIVER; PROPIONIC ACIDS; PROTEIN ISOFORMS;

EID: 44149110127     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019877     Document Type: Article

References (32)

1. Antonian L, Zhang H, Yang C, Wagner G, Shawver LK, Shet M, Ogilvie B, Madan A, and Parkinson A (2000) Biotransformation of the anti-angiogenic compound SU5416. Drug Metab Dispos 28:1505-1512.
2. Bu HZ, Knuth K, Magis L, and Teitelbaum P (2001) High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment. Eur J Pharm Sci 2:447-452.
3. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.
4. Dilger K, Zheng Z, and Klotz U (1999) Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol 48:438-444.
5. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543.
6. Hengstler JG, Ringel M, Biefang K, Hammel S, Milbert U, Gerl M, Klebach M, Diener B, Platt KL, Böttger T, et al. (2000) Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction. Chem Biol Interact 125:51-73.
7. Kern A, Bader A, Pichlmayr R, and Sewing KF (1997) Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 54:761-772.
8. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, and Shin JG (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651-2658.
9. Kitamura R, Yamamoto Y, Nagayama S, and Otagiri M (2007) Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2- dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole- 3-propanoic acid) during oral administration twice a day to rats. Drug Metab Dispos 35:1611-1616.
10. Klint P and Claesson-Welsh L (1999) Signal transduction by fibroblast growth factor receptors. Front Biosci 4:165-177.
11. Lanford RE, Carey KD, Estlack LE, Smith GC, and Hay RV (1989) Analysis of plasma protein and lipoprotein synthesis in long-term primary cultures of baboon hepatocytes maintained in serum-free medium. In Vitro Cell Dev Biol 25:174-182.
12. Li AP, Hartman NR, Lu C, Collins JM, and Strong JM (1999) Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol 48:733-742.
13. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
14. Liu N, Zhang QY, Vakharia D, Dunbar D, and Kaminsky LS (2001) Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 or CYP1A2? Arch Biochem Biophys 389:130-134.
15. Lu C and Li AP (2001) Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134:271-281.
16. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
17. Murakami H, Yamamoto N, Shimoyama T, Ueda Y, Yamada Y, and Tamura T (2003) Phase I, pharmacokinetic, and biological studies of TSU-68, the oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, administered after meals in patients with advanced solid tumors (Abstract). Proc Am Soc Clin Oncol 22:870.
18. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS, and Boobis AR (1993) Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 14:585-592.
19. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, and Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
20. Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C, and Maurel P (2004) The olivacine derivative S 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl]-6Hpyrido( 4,3-B)-carbazole-1- carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos 32:80-88.
21. Ritter JK, Kessler FK, Thompson MT, Grove AD, Auyeung DJ, and Fisher RA (1999) Expression and inducibility of the human bilirubin UDP- glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 30:476-484.
22. Roos PH (2002) Differential induction of CYP1A1 in duodenum, liver and kidney of rats after oral intake of soil containing polycyclic aromatic hydrocarbons. Arch Toxicol 76:75-82.
23. Rosenkranz S and Kazlauskas A (1999) Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and b subtypes. Growth Factors 16:201-216.
24. Runge D, Kohler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, et al. (2000) Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273:333-341.
25. Santostefano MJ, Ross DG, Savas U, Jefcoate CR, and Birnbaum LS (1997) Differential time-course and dose-response relationships of TCDD-induced CYP1B1, CYP1A1, and CYP1A2 proteins in rats. Biochem Biophys Res Commun 233:20-24.
26. Soars MG, Petullo DM, Eckstein JA, Kasper SC, and Wrighton SA (2004) An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32:140-148.
27. Sugihara K, Kitamura S, Yamada T, Okayama T, Ohta S, Yamashita K, Yasuda M, Fujii-Kuriyama Y, Saeki K, Matsui S, et al. (2004) Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo. Biochem Biophys Res Commun 318:571-578.
28. Ueng YF, Don MJ, Jan WC, Wang SY, Ho LK, and Chen CF (2006) Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450. Drug Metab Dispos 34:821-827.
29. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, et al. (2004) A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22:459-466.
30. Xu L, Li AP, Kaminski DL, and Ruh MF (2000) 2,3,7,8- Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes. Chem Biol Interact 124:173-189.
31. Yueh MF, Huang YH, Hiller A, Chen S, Nguyen N, and Tukey RH (2003) Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1. J Biol Chem 278:15001-15006.
32. Zhang ZY, Pelletier RD, Wong YN, Sugawara M, Zhao N, and Littlefield BA (2006) Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem Biophys Res Commun 341:399-407.